Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT

Katrin Resch; Ryan Hung; Jonathan Abele

doi:10.1186/s41824-022-00134-5

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT

Eur J Hybrid Imaging. 2022 Jul 4;6(1):13. doi: 10.1186/s41824-022-00134-5.

Authors

Katrin Resch¹, Ryan Hung¹, Jonathan Abele²

Affiliations

¹ Department of Radiology and Diagnostic Imaging, 2A2.41 WC Mackenzie Health Sciences Centre, University of Alberta, 8440 112 Street NW, Edmonton, AB, T6G 2B7, Canada.
² Department of Radiology and Diagnostic Imaging, 2A2.41 WC Mackenzie Health Sciences Centre, University of Alberta, 8440 112 Street NW, Edmonton, AB, T6G 2B7, Canada. jabele@ualberta.ca.

Abstract

A 62-year-old man with resected, pathology-proven small bowel neuroendocrine tumor underwent 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT to assess metastatic disease. The 111In-pentetreotide SPECT/CT scan showed no metastatic disease. Both 18F-DOPA and 68Ga-HA-DOTATATE PET/CT showed hepatic and peritoneal metastatic disease. However, the burden of 18F-DOPA-avid metastatic disease was far greater compared to the burden of 68Ga-HA-DOTATATE-avid metastatic disease.

Keywords: 177Lu-DOTATATE; 68Ga-HA-DOTATATE; Fluorodopa F 18; Neuroendocrine tumor.